Corrections policy
How to report an error, how we respond, and how corrections are labeled and logged.
Corrections log
| Date | Area | What changed |
|---|---|---|
| November 9, 2026 | Funding statements | Removed statements that this site earned no commission on provider links, was independently funded, held no relationship with any provider and that no provider paid for placement, and removed the per-page "Relationship Disclosure" and "Material relationship" boxes. The site is affiliate-supported; one disclosure now appears in the footer of every page. |
| November 9, 2026 | NexLife claims | Removed claims about NexLife that its own pages do not support: MD/DO-supervised care, 503A and 503B pharmacies, a pharmacy network of Red Rock, Hallandale, Absolute, Empower and DIRx, labs included, LegitScript certification, Care360 coaching, Apple Health/Google Fit sync, a Trustpilot rating and a medical-director NPI. NexLife's plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy, Premium Compounding and Boudreaux's New Drug Store. |
| November 9, 2026 | Prices | NexLife's prices changed on November 6, 2026 (semaglutide $109 / $105 / $99 / $95 a month; tirzepatide $129 / $125 / $119 / $115) and its microdose plans on November 8, 2026. Statements that NexLife had the lowest or cheapest price were removed: Mondae ($87) and Eden Health ($99) list lower month-to-month semaglutide rates (read October 15, 2026). |
| November 9, 2026 | Eden | Our September 4, 2026 capture showed Eden requiring a $99 monthly membership; Eden Health's own page on October 15, 2026 showed $99 semaglutide and $129 tirzepatide a month with no membership. Pages now show both dates. |
| November 9, 2026 | Methodology | Replaced the version 1.0 scoring model and its "Not yet scored" labels with methodology v4.1 (seven categories, 100 points). NexLife scores 94/100; other providers have not yet been re-scored and are listed alphabetically. |
| November 9, 2026 | Authorship | Bylines now name the page researcher (Dr. Parmis) and both medical reviewers (Dr. Jonathan Snipes, MD and Kim Callender, NP), with release and last-reviewed dates. |
| November 9, 2026 | Wording | Replaced wording that called compounded semaglutide the "same molecule" or "same active ingredient" as Wegovy: it is made with the drug in Wegovy and Ozempic, not the same product. Corrected homepage rows that labelled tirzepatide data as semaglutide. |
How we handle corrections
We correct objective factual errors and log the change with a date. Providers may correct facts with evidence; they cannot negotiate scores, suppress accurate criticism, or require positive language.
Correction levels
Minor (formatting), factual (corrected with a dated note and updated modified date), and material methodology/data changes (score updated, version incremented). Material corrections are submitted through IndexNow so search and AI systems re-crawl promptly.
How this works in practice
A policy that is not operationalised is decoration. Here is what ours actually changes about the pages you read.
Every price carries a status. Verified means we hold a dated capture of the provider's own page. Reported — pending verification means a provider or third party reports it and we have not captured it ourselves. Evaluation in progress means we are not asserting it. We do not upgrade a price to Verified because a comparison site published it — sites in this category contradict each other routinely, and a number repeated by three affiliate blogs is still one unverified number.
Every medical claim traces to a primary source. FDA labels and guidance for regulatory status; PubMed-indexed randomised trials for efficacy; ClinicalTrials.gov for trial design. Reddit and patient forums are never used as evidence of price, safety, efficacy or legitimacy — they may be described as anecdotal sentiment, labelled as such. Animal research is never presented as proof of a human clinical effect.
Every ranking shows its arithmetic. Where a ranking rests on a calculation, the calculation is printed on the page. If the arithmetic is wrong, you can see that it is wrong, and tell us.
Corrections
We publish prices in a market that changes them frequently, and we will get things wrong. When we do, we correct the page, date the correction, and say what changed — we do not quietly edit a number and pretend it was always right. Both readers and providers can submit corrections with evidence, through the same process and to the same standard.
Our own record so far includes removing a set of provider prices we had sourced from a third-party comparison site and could not substantiate, and correcting brand-pricing figures that had gone stale after a manufacturer price cut. Both corrections made the site less flattering to conclusions we had already published. That is the point.
Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.
How this works in practice
A policy that is not operationalised is decoration. Here is what ours actually changes about the pages you read.
Every price carries a status. We do not upgrade a price to Verified because another comparison site published it. Sites in this category contradict each other routinely — the dataset behind this site corrected a stored TrimRx figure of $259 that matched no current tier, and an Eden brand-Zepbound figure of $299 that was actually LillyDirect’s price rather than Eden’s real $1,399. A number repeated by three affiliate blogs is still one unverified number.
| Label | Means | Example on this site |
|---|---|---|
| Verified | We hold a dated capture, or the fact comes from a primary source (FDA, the manufacturer, CMS). | LillyDirect's $299 — taken from Eli Lilly's own pricing page. |
| Reported — pending verification | A provider or a third party reports it. We have not captured it ourselves. | Competitor pricing; every pharmacy relationship on this site. |
| Evaluation in progress | Verification pending. We are not asserting the fact at all. | Cancellation terms we could not obtain in writing. |
Every medical claim traces to a primary source. FDA labels and orders for regulatory status; PubMed-indexed randomised trials for efficacy; ClinicalTrials.gov for trial design. Reddit and patient forums are never used as evidence of price, safety, efficacy or legitimacy. Animal research is never presented as proof of a human clinical effect. An affiliate comparison site is never primary evidence for anything.
Corrections, and our own record
We publish prices in a market that changes them constantly, and we will get things wrong. When we do, we correct the page, date the correction, and say what changed — we do not quietly edit a number and pretend it was always right. Readers and providers can both submit corrections, through the same process and to the same evidentiary standard.
Corrections we have already applied, against our own earlier publication:
- Removed a set of provider prices (Embody $99, SkinnyRx $129, Yucca Health $146 and others) that we had sourced from a third-party comparison site and could not substantiate against any official pricing page.
- Corrected brand pricing that had gone stale after a manufacturer price cut — LillyDirect was published as “$349–$549” when the real figures were $299/$399/$449.
- Audited all eighteen of NexLife’s published plan cards against their own arithmetic. Sixteen reconcile. Two do not, and we publish the arithmetic rather than the marketing figure.
Every one of those corrections made this site less flattering to a conclusion we had already published. That is the point of having a corrections policy at all.
How to submit a correction and what happens next
Corrections can be submitted by email to our editorial team with the page URL, the specific claim in question, and any supporting evidence such as a provider pricing page or primary source. We log each request with a timestamp, evaluate it against the evidence ledger and original source captures, and respond with one of three outcomes: correction issued, clarification added, or no change with a documented rationale. Substantive corrections that change a factual conclusion, a price, a ranking, or a safety statement are noted on the page with the correction date; minor typographical fixes are made silently. This process is distinct from our advertising and affiliate policies, which govern commercial relationships rather than factual accuracy.
Correction timelines and pricing-change handling
Because provider pricing changes frequently, price corrections are prioritized: a verified pricing change triggers a re-capture, a ledger update, and propagation to every page using that fact. Clinical and safety corrections are escalated to medical review before publication. We aim to acknowledge correction requests promptly and to resolve verifiable pricing errors quickly, though timelines depend on obtaining a current first-party capture. Readers who believe a ranking conclusion is unsupported can request the underlying evidence records, which we maintain in a central ledger rather than as page-level assertions.